Gilead Science vies for purchase of Pharmasset
Biotechnology firm Gilead Sciences, the leading maker of HIV drugs, has announced its plans to acquire a rival firm, Pharmasset, for $11 billion.
Many firms had vied for the right to...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch